SillaJen Inc (215600 KQ) stock market data APIs
₩3346.2426
19.8(0.6%)
as of September 17, 2025
Try our APIs with
free plan!
SillaJen Inc Financial Data Overview
Price chart is built with
Anychart
SillaJen, Inc. develops and commercializes oncolytic immunotherapy products in South Korea. Its lead product is Pexa-Vec for the treatment of solid tumors and induction of cancer specific antibodies. The company also develops BAL0891, a dual TTK/PLK inhibitor; SJ-600 to improve the intravenous administration efficiency of anticancer viruses; JX-970 for the treatment of tumor tissues; and JX-900 is a series of modified vaccinia vaccine. SillaJen, Inc. was founded in 2006 and is headquartered in Seoul, South Korea.
Prev. Close
3346.2426
Open
3366.0471
High
3508.3551
Low
3269.5898
52 wk Range
1873-4700
Market Cap
447 126 M
Shares Outstanding
138 M
Revenue
6 367 M
EPS
-39.8856
Beta
0.054
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get SillaJen Inc data using free add-ons & libraries
Get SillaJen Inc Fundamental Data
SillaJen Inc Fundamental data includes:
- Net Revenue: 6 367 M
- EBITDA: -25 497 798 656
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-11
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
SillaJen Inc News
New
Basilea announces acquisition of rights for oncology asset BAL0891 by SillaJen and updates financial guidance
Upfront and near-term milestone payments of USD 14 million Additional milestone payments of approximately USD 320 million and tiered royalties on net salesSecond oncology transaction as part of strate...
Basilea gibt Verkauf der Rechte an Onkologie-Wirkstoff BAL0891 an SillaJen bekannt und aktualisiert Finanzausblick
Abschlags- und kurzfristige Meilensteinzahlungen von USD 14 Mio. Weitere Meilensteinzahlungen in Höhe von rund USD 320 Mio. und gestaffelte Lizenzgebühren auf NettoumsätzeZweite Onkologie-Transakti...
Basilea announces acquisition of rights for oncology asset BAL0891 by SillaJen and updates financial guidance
Basilea Pharmaceutica AG Upfront and near-term milestone payments of USD 14 million Additional milestone payments of approximately USD 320 million and tiered royalties on net sales Second oncology t...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
